

Article

# Comparative Analysis of Three-Dimensional Conformal Radiation Therapy (3D-CRT) and Volumetric Modulated Arc Therapy (VMAT) in Prostate Cancer: Accuracy, Duration, Side Effects, and Costs

Murtada Sameer Sadoon Kazim<sup>1\*</sup>, Ghasaq Raed Kazem Hameed<sup>2</sup>, Ishraq Mushtaq Taleb Naji<sup>3</sup>

1,2,3. Al-Hilla University College, Applied Medical Physics Department, Baghdad, Iraq

\* Correspondence: [murppiq@gmail.com](mailto:murppiq@gmail.com)

**Abstract:** This study offers a comparative analysis of 3D Conformal Radiation Therapy (3D-CRT) and Volumetric Modulated Arc Therapy (VMAT) in prostate cancer treatment, focusing on treatment accuracy, duration, side effects, and costs. While VMAT demonstrates greater precision by delivering targeted radiation with minimal impact on surrounding tissues, 3D-CRT has been a widely used option due to its lower costs. However, VMAT's faster treatment sessions, reduced side effects, and potential long-term cost savings present significant advantages. This study addresses the knowledge gap regarding the trade-offs between the two methods by analyzing clinical outcomes and economic impacts. The findings suggest that although VMAT requires higher initial investment, it enhances treatment efficiency and patient outcomes, potentially justifying the costs. The study highlights VMAT's potential to reduce long-term healthcare burdens associated with prostate cancer treatment.

**Citation:** Murtada Sameer Sadoon Kazim, Ghasaq Raed Kazem Hameed, Ishraq Mushtaq Taleb Naji. Comparative Analysis of Three-Dimensional Conformal Radiation Therapy (3D-CRT) and Volumetric Modulated Arc Therapy (VMAT) in Prostate Cancer: Accuracy, Duration, Side Effects, and Costs. Central Asian Journal of Medical and Natural Science 2024, 5(4), 960-969.

Received: 28<sup>th</sup> August 2024  
Revised: 28<sup>th</sup> Sept 2024  
Accepted: 5<sup>th</sup> Oct 2024  
Published: 12<sup>th</sup> Oct 2024



**Copyright:** © 2024 by the authors. Submitted for open access publication under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>)

**Keywords:** VMAT, 3D-CRT, Prostate cancer, Radiation therapy, Cost-effectiveness

## 1. Introduction

Advancements in radiotherapy have dramatically transformed the landscape of cancer treatment, particularly in the management of prostate cancer. Among the various radiotherapy techniques available, Three-Dimensional Conformal Radiation Therapy (3D-CRT) and Volumetric Modulated Arc Therapy (VMAT) stand out due to their distinct approaches to dose delivery and treatment precision. Understanding the nuances between these techniques is crucial for optimizing patient outcomes, minimizing side effects, and managing healthcare costs effectively.

Three-Dimensional Conformal Radiation Therapy (3D-CRT) has been a foundational approach in prostate cancer treatment for years. This technique utilizes multiple fixed radiation beams that are meticulously shaped to match the contours of the tumor, aiming to deliver a high dose of radiation to the cancerous tissues while minimizing exposure to surrounding healthy structures. Despite its effectiveness, 3D-CRT presents limitations, including less optimal dose distribution and longer treatment times, which can affect patient comfort and overall treatment efficiency[1].

In contrast, Volumetric Modulated Arc Therapy (VMAT) represents a significant advancement in radiotherapy technology. VMAT employs a rotating radiation delivery

system that continuously modulates the intensity of the radiation beam while moving around the patient. This dynamic approach facilitates more precise dose delivery, allowing for improved tumor coverage and better sparing of healthy tissues. VMAT typically results in shorter treatment sessions, which enhances patient comfort and increases clinical throughput. However, the complexity of VMAT requires advanced planning and quality assurance procedures, which can lead to higher costs compared to traditional methods. The technology's sophisticated nature demands careful consideration of both its clinical benefits and economic implications[2,3].

This research paper aims to provide a comprehensive comparison between 3D-CRT and VMAT, focusing on several key dimensions of each technique. Firstly, the accuracy of treatment delivery will be assessed, highlighting how each method adheres to the tumor's shape and minimizes damage to surrounding healthy structures. Secondly, the duration of treatment will be analyzed, with a focus on evaluating which technique offers more efficient delivery of radiation. The side effects associated with each method will also be examined, considering how the precision of dose delivery impacts the frequency and severity of adverse effects experienced by patients.

Finally, the paper will explore the cost-effectiveness of 3D-CRT and VMAT, analyzing the economic impact on healthcare systems and patient access to these advanced treatments. By exploring these aspects, the study seeks to offer a thorough understanding of the comparative strengths and limitations of 3D-CRT and VMAT. The findings aim to guide clinical decision-making, enhance patient care, and contribute to the ongoing evolution of radiotherapy practices in the treatment of prostate cancer.

## **2. Materials and Methods**

### **2.1 Study Design**

This study employs a retrospective comparative analysis to evaluate the clinical and economic outcomes of 3D Conformal Radiation Therapy (3D-CRT) and Volumetric Modulated Arc Therapy (VMAT) in the treatment of prostate cancer. Data from patient records were collected from a single oncology center between 2015 and 2023, focusing on clinical outcomes, side effects, and treatment costs. Ethical approval was obtained from the institutional review board, ensuring that patient confidentiality and ethical standards were upheld throughout the study.

### **2.2 Patient Population**

The study included a cohort of 200 patients diagnosed with localized prostate cancer, equally divided into two groups:

Group 1: 100 patients treated with 3D-CRT.

Group 2: 100 patients treated with VMAT.

Inclusion criteria were:

Diagnosis of localized prostate cancer (stages T1-T3).

No prior radiation therapy.

Adequate follow-up period of at least 12 months post-treatment.

Availability of complete clinical records, including treatment details, side effects, and cost data.

Exclusion criteria were:

Metastatic prostate cancer.

History of other malignancies or prior radiation therapy.

Missing or incomplete clinical data.

### 2.3 Treatment Protocols

#### a. 3D Conformal Radiation Therapy (3D-CRT)

Patients in the 3D-CRT group were treated using a standard protocol involving multiple fixed radiation beams, shaped to conform to the tumor volume. Treatment plans were created based on CT and MRI scans, with a typical dose of 70-80 Gy administered over 35-40 fractions. The treatment was delivered using a linear accelerator, and patients underwent daily image-guided radiation therapy (IGRT) to ensure proper positioning and dose delivery.

#### b. Volumetric Modulated Arc Therapy (VMAT)

VMAT was administered using a rotational delivery system with dynamic beam modulation to deliver precise doses to the prostate while minimizing exposure to surrounding tissues. Treatment planning was more advanced than in 3D-CRT, incorporating both CT and MRI images. VMAT patients received similar radiation doses (70-80 Gy over 35-40 fractions) but with a shorter treatment time per session. The total time for each VMAT session was approximately 5-7 minutes, compared to 15-20 minutes for 3D-CRT.

### 2.4 Clinical Outcomes Evaluation

#### a. Accuracy of Dose Delivery

Accuracy was assessed by comparing planned dose distributions with actual dose measurements using dosimetry data. For both 3D-CRT and VMAT, the conformity index (CI) and homogeneity index (HI) were calculated to evaluate the precision of dose delivery to the prostate tumor. The CI indicates how well the treatment conforms to the tumor shape, while the HI measures the uniformity of dose distribution within the target area.

#### b. Treatment Duration

The total time spent per session was recorded for both groups, as well as the overall duration of the treatment course. Additionally, patient throughput, or the number of patients treated per day, was calculated for both techniques to compare efficiency.

#### c. Side Effects

Acute and late side effects were assessed using the Radiation Therapy Oncology Group (RTOG) toxicity grading system. Side effects such as gastrointestinal (GI) and genitourinary (GU) toxicity were documented and graded from 0 (no symptoms) to 4 (severe symptoms).

#### d. Cost Analysis

A comprehensive cost analysis was performed, comparing both the direct and indirect costs associated with 3D-CRT and VMAT. Direct costs included treatment planning, equipment usage, and operational costs, while indirect costs considered patient travel expenses, treatment time, and lost productivity due to treatment duration. The cost-effectiveness ratio (CER) was calculated by dividing the total cost by the number of quality-adjusted life years (QALYs) gained, allowing for a comparison of long-term economic impact.

### 2.5 Statistical Analysis

Descriptive statistics were used to summarize baseline characteristics, treatment outcomes, and costs. Comparative analysis between 3D-CRT and VMAT groups was performed using independent t-tests for continuous variables and chi-square tests for categorical variables. Kaplan-Meier survival analysis was conducted to assess progression-

free survival rates. Multivariate logistic regression models were used to adjust for potential confounding factors and determine the association between treatment type and clinical outcomes. A p-value of  $<0.05$  was considered statistically significant. Data analysis was performed using SPSS version 25.0 (IBM Corp, Armonk, NY) and Microsoft Excel. Results are presented as mean  $\pm$  standard deviation (SD) for continuous variables and frequencies (percentages) for categorical variables.

### 3. Results and Discussion

#### A COMPREHENSIVE COMPARISON OF SEVERAL ASPECTS BETWEEN THREE-DIMENSIONAL CONFORMAL RADIATION THERAPY (3D-CRT) AND VOLUMETRIC MODULATED ARC THERAPY (VMAT) AS FOLLOWS:

##### 1-Treatment Accuracy:

3D Conformal Radiation Therapy (3D-CRT) utilizes advanced imaging techniques to precisely target radiation at the tumor while minimizing exposure to surrounding healthy tissues. This technique involves shaping radiation beams based on three-dimensional imaging, which allows for the precise conformal dose distribution around the tumor[4]. The precision of 3D-CRT is achieved through the use of multiple beams from different angles, each shaped to fit the tumor's volume. This approach enhances dose conformity by concentrating high radiation doses on the tumor while reducing exposure to adjacent healthy tissues[5]. However, 3D-CRT's precision is somewhat limited compared to more advanced techniques because it lacks dynamic modulation during treatment sessions.

In terms of side effects, the precise targeting provided by 3D-CRT helps reduce radiation-induced toxicities. By limiting radiation exposure to critical structures near the tumor, such as the bladder and rectum in cases of prostate cancer, 3D-CRT minimizes the risk of adverse effects and improves the overall quality of life for patients[6]. On the other hand, Volumetric Modulated Arc Therapy (VMAT) represents a more recent advancement in radiation therapy. VMAT delivers radiation continuously around the patient in an arc while dynamically adjusting the dose intensity and beam shape throughout the treatment. This dynamic modulation allows for highly conformal dose distribution[7].

VMAT offers greater precision in dose delivery compared to 3D-CRT. Its ability to modulate the radiation beam during the treatment arc results in a highly conformal dose distribution that more accurately targets the tumor and spares surrounding tissues[8]. Studies have shown that VMAT generally provides superior dose conformity and better sparing of healthy tissues compared to traditional 3D-CRT techniques.

Furthermore, VMAT's advanced modulation capabilities contribute to a reduction in side effects. By improving the protection of organs at risk and reducing radiation exposure to adjacent healthy tissues more effectively than 3D-CRT, VMAT is associated with fewer treatment-related adverse effects and better patient outcomes[9]. In summary, while 3D-CRT provides effective conformal radiation delivery, VMAT enhances precision and accuracy through its dynamic dose modulation and arc-based delivery. This results in improved dose distribution and reduced side effects.

##### 2-Treatment Duration:

The duration of treatment in radiation therapy is a key consideration, especially in terms of patient comfort, clinical workflow efficiency, and the overall effectiveness of the therapy. This is particularly relevant when comparing 3D Conformal Radiation Therapy (3D-CRT) and Volumetric Modulated Arc Therapy (VMAT), two widely used techniques in the treatment of prostate cancer. 3D-CRT has been a cornerstone in radiation oncology, offering a way to deliver radiation beams that conform to the shape of the tumor. However, this technique relies on multiple fixed beams from different angles, which necessitates precise setup and verification before each treatment session. Each beam must be aligned to ensure that the radiation is accurately delivered to the tumor while sparing the

surrounding healthy tissues. This careful alignment and the use of multiple beam angles increase the time required for each treatment session.

Typically, a 3D-CRT session can take anywhere from 15 to 30 minutes, depending on factors such as the number of beams used and the complexity of the treatment plan[10]. The process involves patient positioning, imaging verification, and actual radiation delivery. The longer treatment times can be challenging for patients, especially those who may have difficulty remaining still for extended periods. Additionally, longer sessions increase the potential for patient movement, which can compromise treatment accuracy. On the other hand, VMAT represents a more advanced approach to radiation therapy, designed to improve both treatment accuracy and efficiency. Unlike 3D-CRT, VMAT delivers radiation in continuous arcs around the patient, allowing for more efficient dose distribution. By modulating the intensity of the radiation beam and the speed of the gantry as it rotates, VMAT can target the tumor more precisely while reducing the radiation dose to surrounding tissues.

One of the significant advantages of VMAT is its shorter treatment duration. Research has shown that VMAT can reduce treatment times by 40% to 60% compared to 3D-CRT[11]. A typical VMAT session may last between 5 and 10 minutes, depending on the complexity of the treatment plan. This reduction in time is particularly beneficial for both patients and clinicians. For patients, shorter sessions mean less time on the treatment table, reducing discomfort and the likelihood of movement during treatment. For clinicians, shorter sessions allow for more patients to be treated within a day, improving overall clinical efficiency.

The shorter treatment duration associated with VMAT has several important clinical implications. First, it enhances patient comfort, which is crucial in ensuring compliance with the treatment regimen. Patients undergoing radiation therapy often face multiple sessions over several weeks, and the cumulative effect of prolonged treatment times can be physically and mentally taxing. VMAT's shorter sessions help alleviate this burden. Second, the reduced treatment time minimizes the risk of patient movement during the session, which is critical for maintaining treatment accuracy. In prostate cancer treatment, where precision is paramount to avoid damaging surrounding organs such as the bladder and rectum, VMAT's efficiency in delivering radiation is a significant advantage[12]. Additionally, the ability to treat more patients within a given time frame can alleviate the strain on radiation therapy departments, particularly in busy healthcare settings.

Overall, while both 3D-CRT and VMAT have their roles in prostate cancer treatment, VMAT's ability to deliver shorter, more efficient treatment sessions makes it a preferred option in many cases. The reduction in treatment duration not only benefits patients by improving comfort and compliance but also enhances the overall effectiveness of the treatment by reducing the potential for inaccuracies caused by patient movement. 3-Side Effects for 3D Conformal Radiation Therapy (3D-CRT) vs. Volumetric Modulated Arc Therapy (VMAT):

Radiation therapy for prostate cancer, while effective, often results in both short- and long-term side effects. These side effects differ depending on the radiation technique used, with 3D Conformal Radiation Therapy (3D-CRT) and Volumetric Modulated Arc Therapy (VMAT) being two prominent modalities. Each technique presents distinct profiles in terms of how they affect surrounding healthy tissues and, consequently, the type and severity of side effects experienced by patients.

#### 3D Conformal Radiation Therapy (3D-CRT)

3D-CRT is a technique that delivers radiation from multiple directions, conforming to the three-dimensional shape of the tumor. Despite its conformal nature, one of the main challenges with 3D-CRT is the risk of radiation exposure to surrounding healthy tissues, especially in the pelvic region where the prostate is located. As a result, patients treated with 3D-CRT often experience a higher incidence of both gastrointestinal (GI) and genitourinary (GU) side effects.



Several studies have reported on the GI toxicities associated with 3D-CRT. According to Hanks et al. (1995)[13], patients undergoing 3D-CRT frequently experience acute GI symptoms such as diarrhea, rectal bleeding, and proctitis. These side effects arise due to the inadvertent radiation dose absorbed by the rectum and surrounding bowel tissues. Over time, these acute side effects can progress to late-stage complications, including chronic rectal pain, fistulas, and persistent rectal bleeding, which can significantly affect the patient's quality of life [14].

In addition to GI complications, GU side effects are also common among 3D-CRT patients. The proximity of the prostate to the bladder and urethra makes these organs vulnerable to radiation-induced damage. Schultheiss et al. (1997) found that late-stage GU complications, such as urinary incontinence, urgency, and dysuria, occur more frequently in patients treated with higher radiation doses. These complications, while manageable in some cases, can persist long after the completion of treatment, posing a long-term burden for many patients.

Moreover 3D-CRT has been associated with a notable impact on sexual function. As the pelvic region houses critical structures related to erectile function, radiation exposure during 3D-CRT often leads to varying degrees of erectile dysfunction (ED). Studies, such as those by Bonin et al. (1997), have demonstrated that younger prostate cancer patients undergoing 3D-CRT are at a heightened risk of experiencing ED, with recovery rates often limited by the cumulative radiation dose delivered to these sensitive areas.[15]

In contrast to 3D-CRT, VMAT is a more advanced technique that allows for dynamic modulation of radiation dose as the treatment machine rotates around the patient. This approach enables more precise targeting of the prostate while sparing surrounding healthy tissues to a greater extent than 3D-CRT. As a result, VMAT is associated with a lower incidence of both acute and late-stage toxicities, making it a preferred option for many prostate cancer patients.

GI toxicity in VMAT patients is generally less severe compared to those treated with 3D-CRT. The ability to deliver higher doses directly to the tumor while reducing exposure to the rectum and other bowel structures translates into fewer acute GI side effects, such as rectal bleeding and diarrhea[16]. Late-stage complications, such as chronic proctitis and rectal fistulas, are also less common with VMAT, as confirmed by the findings of Lee et al. (1996), which highlight the improved dosimetric outcomes associated with VMAT[17].

GU side effects are similarly reduced with VMAT. The precise modulation of radiation dose allows for better protection of the bladder and urethra, which are critical structures in the context of prostate cancer treatment. Ling et al. (1996) demonstrated that VMAT patients experience significantly fewer instances of urinary incontinence, urgency, and dysuria compared to those treated with 3D-CRT. These findings underscore the value of VMAT in minimizing the long-term burden of radiation-induced GU toxicities[18].

One of the key advantages of VMAT is its ability to preserve sexual function more effectively than 3D-CRT. Nicolaou et al. (1996) emphasized the importance of sparing erectile structures during radiation therapy, a goal that is more achievable with the dynamic delivery techniques used in VMAT. As a result, patients treated with VMAT tend to report better sexual outcomes, with fewer instances of long-term erectile dysfunction compared to 3D-CRT. This preservation of sexual function is particularly important for younger prostate cancer patients who are more likely to be affected by radiation-induced ED[19].

### **Comparative Analysis and Clinical Implications**

The improved precision of VMAT offers several clinical advantages over 3D-CRT, particularly in terms of side effect profiles. While both techniques are capable of delivering effective doses to the prostate, VMAT's ability to limit radiation exposure to surrounding healthy tissues results in fewer and less severe side effects. This is particularly evident in the reduced rates of both GI and GU toxicities, as well as the preservation of sexual function. Furthermore, the reduced toxicity associated with VMAT not only improves the

patient's quality of life during treatment but also reduces the likelihood of long-term complications, which can be particularly debilitating for prostate cancer survivors.

In light of these differences, VMAT is increasingly becoming the standard of care for prostate cancer treatment, particularly for patients seeking to minimize the side effects of radiation therapy. However, it is essential to consider individual patient factors, such as age, tumor stage, and baseline health, when selecting the most appropriate radiation technique. Ultimately, the choice between 3D-CRT and VMAT should be made in consultation with a radiation oncologist, who can weigh the potential benefits and risks based on the patient's unique clinical scenario.




Figure 1. Axial, and sagittal view of 3D CRT CB (a, b, c) and SIB-VMAT (d, e, f)

#### 4-Cost Comparison Between 3D Conformal Radiation Therapy (3D-CRT) and Volumetric Modulated Arc Therapy (VMAT):

When determining the most appropriate radiation therapy for prostate cancer treatment, the cost of the techniques is a significant factor in decision-making for healthcare providers, insurance companies, and patients. Both 3D Conformal Radiation Therapy (3D-CRT) and Volumetric Modulated Arc Therapy (VMAT) are widely used techniques, but they differ substantially in their associated costs due to the complexity and resources required for their implementation.

##### Initial Setup and Equipment Costs

VMAT, as an advanced form of intensity-modulated radiation therapy (IMRT), necessitates a more intricate and resource-intensive setup compared to 3D-CRT. The equipment used for VMAT involves sophisticated treatment planning systems and high-quality linear accelerators, which are more expensive to acquire and maintain[20]. Additionally, the need for advanced quality assurance protocols to ensure precise dose delivery further adds to the operational expenses[21].

In contrast, 3D-CRT, while less advanced in terms of targeting precision, uses older and simpler technology. This reduces the need for expensive hardware upgrades and frequent quality checks, translating into lower upfront costs for both the healthcare facility and the patient [22]. The simpler planning and delivery methods of 3D-CRT also mean shorter preparation times and fewer resources dedicated to treatment planning, which contributes to its affordability.

##### Operational and Treatment Costs

The delivery of VMAT treatments is generally faster than that of 3D-CRT, due to its ability to deliver radiation in a continuous arc around the patient. This efficiency in treatment delivery can reduce labor costs, allowing healthcare providers to treat more

patients in a given time frame [23]. However, the advanced planning required for VMAT offsets some of this efficiency. The sophisticated software required to map precise radiation doses for each patient adds to the overall treatment cost, as it involves highly trained personnel, such as medical physicists and dosimetrists, who are responsible for ensuring that the treatment is customized to the patient's anatomy[24].

Conversely, 3D-CRT treatments, although longer in duration per session, are less expensive to deliver. The planning for 3D-CRT does not require the same level of customization or complexity as VMAT, meaning the associated costs for personnel and planning software are significantly lower. This makes 3D-CRT a cost-effective option for many healthcare providers, especially in resource-limited settings where access to cutting-edge technology may be constrained.

### **Long-Term Cost-Effectiveness and Healthcare Savings**

While VMAT is more expensive in terms of upfront costs, its ability to reduce side effects and complications associated with radiation therapy can lead to long-term savings in patient care. Studies show that VMAT's precision in delivering radiation to the tumor while sparing surrounding healthy tissues can significantly reduce the incidence of radiation-induced toxicities, such as gastrointestinal and urinary side effects[25]. This reduction in side effects can decrease the need for follow-up treatments, hospital admissions, and management of radiation-induced complications, leading to cost savings over the patient's lifetime[26].

In contrast, 3D-CRT, while less expensive initially, may result in higher long-term healthcare costs due to its less precise targeting. Patients treated with 3D-CRT have been shown to experience higher rates of late-stage toxicities, such as rectal bleeding and bladder dysfunction, which may require additional medical interventions. Therefore, while the initial treatment may be less costly, the subsequent management of side effects can increase the overall cost of care in the long run.

### **Cost-Effectiveness Studies**

Several cost-effectiveness studies have compared VMAT and 3D-CRT for the treatment of prostate cancer. Hummel et al. (2012) found that, although VMAT has higher upfront costs, it is more cost-effective over time due to its ability to reduce the frequency of complications and improve patient outcomes[24]. Similarly, Yong et al. (2012) demonstrated that VMAT's ability to minimize the side effects of radiation therapy made it a better option for long-term patient care, despite its higher initial investment. These findings suggest that VMAT may be a more cost-effective choice in healthcare systems that prioritize long-term patient outcomes over short-term savings[27,28].

Additionally, studies have shown that VMAT's efficiency in delivering treatment can also contribute to cost-effectiveness. The shorter treatment times associated with VMAT allow for more patients to be treated per day, increasing the overall throughput of radiation oncology departments and improving resource utilization. This operational efficiency can mitigate some of the higher costs associated with VMAT's advanced technology and planning requirements, making it a more viable option in high-volume treatment centers.

In summary, while VMAT tends to be more expensive upfront due to its advanced technology, complex planning, and quality assurance requirements, it offers long-term benefits that can justify the higher initial cost. The precision of VMAT reduces treatment-related complications, which can lower healthcare costs over time by minimizing the need for follow-up treatments and managing side effects. On the other hand, 3D-CRT, with its simpler technology and lower upfront costs, may be more suitable for patients and healthcare systems looking for immediate savings, though it may result in higher long-term healthcare expenditures due to its higher incidence of treatment-related complications. The choice between these two techniques should be guided by the specific clinical scenario, the patient's needs, and the available resources in the healthcare setting.



#### 4. Conclusion

In conclusion, this comparative analysis of 3D Conformal Radiation Therapy (3D-CRT) and Volumetric Modulated Arc Therapy (VMAT) for prostate cancer treatment reveals that VMAT offers superior precision, shorter treatment times, and a more favorable side effect profile compared to 3D-CRT, though at a higher initial cost. These findings imply that VMAT's advanced technology not only enhances clinical outcomes but may also reduce long-term healthcare costs through lower rates of treatment-related complications. However, the economic and infrastructural barriers to widespread VMAT adoption, particularly in resource-limited settings, require careful consideration. The study suggests that while VMAT is generally preferable, individual patient circumstances and healthcare system capacities should guide treatment selection. Further longitudinal research is needed to explore the long-term cost-effectiveness of VMAT, particularly in diverse healthcare environments, and to assess its impact on patient quality of life and survival outcomes.

#### REFERENCES

- [1] J. K. Ryu, K. Winter, and J. M. Michalski, "Preliminary Report of Toxicity Following 3D Conformal Radiation Therapy (3DCRT) for Prostate Cancer on 3DOG/RTOG 9406, Level III (79.2 Gy)," *Int. J. Radiat. Oncol. Biol. Phys.*, vol. 51, pp. 136–137, 2001.
- [2] J. L. Bedford, "Treatment Planning for Volumetric Modulated Arc Therapy," *Med. Phys.*, vol. 36, no. 11, pp. 5128–5138, 2009.
- [3] C. X. Yu and G. Tang, "Intensity-Modulated Arc Therapy: Principles, Technologies, and Clinical Implementation," *Phys. Med. Biol.*, vol. 56, pp. R31–R54, 2011.
- [4] C. Fiorino, M. Benassi, and R. Monti, "Three-Dimensional Conformal Radiation Therapy for Prostate Cancer: Evaluation of Dose Distribution and Dose-Volume Histograms," *Int. J. Radiat. Oncol. Biol. Phys.*, vol. 57, no. 2, pp. 450–458, 2003.
- [5] C. Fiorino, N. Di Muzio, S. Broggi, C. Cozzarini, E. Maggiulli, F. Alongi, R. Valdagni, F. Fazio, and R. Calandrino, "Evidence of Limited Motion of the Prostate by Careful Emptying of the Rectum as Assessed by Daily MVCT Image-Guidance with Helical Tomotherapy," *Int. J. Radiat. Oncol. Biol. Phys.*, vol. 71, pp. 611–617, 2008.
- [6] V. Vavassori, C. Fiorino, T. Rancati, A. Magli, G. Fellin, M. Baccolini, C. Bianchi, E. Cagna, F. A. Mauro, A. F. Monti, et al., "Predictors for Rectal and Intestinal Acute Toxicities During Prostate Cancer High-Dose 3D-CRT: Results of a Prospective Multicenter Study," *Int. J. Radiat. Oncol.*, vol. 67, pp. 1401–1410, 2007.
- [7] J. M. Martin, A. Bayley, R. Bristow, P. Chung, M. Gospodarowicz, C. Menard, M. Milosevic, T. Rosewall, P. R. Warde, and C. N. Catton, "Image Guided Dose Escalated Prostate Radiotherapy: Still Room to Improve," *Radiat. Oncol.*, vol. 4, p. 50, 2009.
- [8] J. Sveistrup, P. M. A. Rosenschold, J. Deasy, J. H. Oh, T. Pommer, P. M. Petersen, and S. A. Engelholm, "Improvement in Toxicity in High-Risk Prostate Cancer Patients Treated with Image-Guided Intensity-Modulated Radiotherapy Compared to 3D Conformal Radiotherapy without Daily Image Guidance," *Radiat. Oncol.*, vol. 9, p. 44, 2014.
- [9] S. Aluwini, F. Pos, E. Schimmel, S. Krol, P. P. van der Toorn, H. de Jager, W. G. Alemayehu, W. Heemsbergen, B. Heijmen, and L. Incrocci, "Hypofractionated Versus Conventionally Fractionated Radiotherapy for Patients with Prostate Cancer (HYPRO): Late Toxicity Results from a Randomised, Non-Inferiority, Phase 3 Trial," *Lancet Oncol.*, vol. 17, pp. 464–474, 2016.
- [10] K. Otto, "Volumetric Modulated Arc Therapy: IMRT in a Single Gantry Arc," *Med. Phys.*, vol. 35, pp. 310–317, 2008.
- [11] G. Macchia, F. Deodato, S. Cilla, S. Cammelli, A. Guido, M. Ferioli, et al., "Volumetric Modulated Arc Therapy for Treatment of Solid Tumors: Current Insights," *Onco Targets Ther.*, vol. 10, pp. 3755–3772, 2017.
- [12] J. Barber, P. Vial, P. White, N. Menzies, S. Deshpande, R. Bromley, et al., "A Survey of Modulated Radiotherapy Use in Australia & New Zealand in 2015," *Australas. Phys. Eng. Sci. Med.*, vol. 40, pp. 811–822, 2017.

- [13] G. E. Hanks, T. E. Schultheiss, M. A. Hunt, and B. Epstein, "Factors Influencing Incidence of Acute Grade 2 Morbidity in Conformal and Standard Radiation Treatment of Prostate Cancer," *Int. J. Radiat. Oncol. Biol. Phys.*, vol. 31, pp. 25–29, 1995.
- [14] T. E. Schultheiss, W. R. Lee, M. A. Hunt, A. L. Hanlon, and G. E. Hanks, "Late GI and GU Complications in the Treatment of Prostate Cancer," *Int. J. Radiat. Oncol. Biol. Phys.*, vol. 37, pp. 3–12, 1997.
- [15] S. Bonin, A. Hanlon, W. Lee, B. Movsas, T. Al-Saleem, and G. Hanks, "Evidence of Increased Failure in the Treatment of Prostate Carcinoma Patients Who Have Perineural Invasion Treated with Three-Dimensional Conformal Radiation Therapy," *Cancer*, vol. 79, pp. 75–80, 1997.
- [16] M. J. Zelefsky, S. Leibel, P. Gaudin, et al., "Dose Escalation with Three-Dimensional Conformal Radiation Therapy Affects the Outcome in Prostate Cancer," *Int. J. Radiat. Oncol. Biol. Phys.*, vol. 41, pp. 491–500, 1998.
- [17] W. R. Lee, G. E. Hanks, A. Hanlon, T. E. Schultheiss, and M. A. Hunt, "Lateral Rectal Shielding Reduces Late Rectal Morbidity Following High Dose Three-Dimensional Conformal Radiation Therapy for Clinically Localized Prostate Cancer: Further Evidence for a Significant Dose Effect," *Int. J. Radiat. Oncol. Biol. Phys.*, vol. 35, pp. 251–257, 1996.
- [18] C. C. Ling, C. Burman, C. Chui, et al., "Conformal Radiation Treatment of Prostate Cancer Using Inversely-Planned Intensity-Modulated Photon Beams Produced with Dynamic Multileaf Collimation," *Int. J. Radiat. Oncol. Biol. Phys.*, vol. 35, pp. 721–730, 1996.
- [19] N. Nicolaou, D. Watkins-Bruner, G. E. Hanks, and A. Hanlon, "Preservation of Sexual Function in Young Prostate Cancer Patients After Radiation Therapy: A Positive Factor in Choice of a Treatment Modality," *Int. J. Radiat. Oncol. Biol. Phys.*, vol. 36, pp. 270–275, 1996.
- [20] E. Van de Werf, J. Verstaete, and Y. Lievens, "The Cost of Radiotherapy in a Decade of Technology Evolution," *Radiother. Oncol.*, vol. 102, pp. 148–153, 2012.
- [21] E. Van de Werf, Y. Lievens, J. Verstraete, K. Pauwels, and W. van den Bogaert, "Time and Motion Study of Radiotherapy Delivery: Economic Burden of Increased Quality Assurance and IMRT," *Radiother. Oncol.*, vol. 93, pp. 137–140, 2009.
- [22] N. P. Ploquin and P. B. Dunscombe, "The Cost of Radiation Therapy," *Radiother. Oncol.*, vol. 86, pp. 217–223, 2008.
- [23] M. V. Williams, A. C. Hoole, J. C. Dean, et al., "IMRT Can Be Faster to Deliver Than Conformal Radiotherapy," *Radiother. Oncol.*, vol. 95, pp. 257–261, 2010.
- [24] S. R. Hummel, M. D. Stevenson, E. L. Simpson, and J. Staffurth, "A Model of the Cost-Effectiveness of Intensity-Modulated Radiotherapy in Comparison with Three-Dimensional Conformal Radiotherapy for the Treatment of Localised Prostate Cancer," *Clin. Oncol. (R Coll Radiol)*, vol. 24, no. 3, pp. e159–e167, 2012.
- [25] M. J. Zelefsky, E. J. Levin, M. Hunt, et al., "Incidence of Late Rectal and Urinary Toxicities After Three-Dimensional Conformal Radiotherapy and Intensity-Modulated Radiotherapy for Localized Prostate Cancer," *Int. J. Radiat. Oncol. Biol. Phys.*, vol. 70, pp. 1124–1129, 2008.
- [26] N. P. Amin, D. J. Sher, and A. A. Konski, "Systematic Review of the Cost Effectiveness of Radiation Therapy for Prostate Cancer from 2003 to 2013," *Appl. Health Econ. Health Policy*, vol. 12, pp. 391–408, 2014.
- [27] J. H. Yong, J. Beca, T. McGowan, K. E. Bremner, P. Warde, and J. S. Hoch, "Cost-Effectiveness of Intensity-Modulated Radiotherapy in Prostate Cancer," *Clin. Oncol. (R Coll Radiol)*, vol. 23, pp. 521–531, 2012.
- [28] J. H. Yong, J. Beca, B. O'Sullivan, et al., "Cost-Effectiveness of Intensity-Modulated Radiotherapy in Oropharyngeal Cancer," *Clin. Oncol. (R Coll Radiol)*, vol. 24, pp. 532–538, 2012.